Suppression of T cell immunity during sepsis

败血症期间 T 细胞免疫的抑制

基本信息

  • 批准号:
    8601255
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-10-01 至 2016-09-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Sepsis is the leading cause of death in most intensive care units, and the death of septic patients usually does not result from the initial septic event but rather from subsequent nosocomial infections. Patients who survive severe sepsis often display severely compromised immune function. Not only is there significant apoptosis of lymphoid and myeloid cells that depletes critical components of the immune system during sepsis, there is also decreased function of the remaining immune cells. Studies in animals and humans suggest the immune defects that occur during sepsis may be critical to the pathogenesis and subsequent mortality. Using a cecal-ligation and puncture (CLP) model to induce intra-abdominal peritonitis, we recently established a mechanistic link between apoptotic cells generated during sepsis and the establishment of sepsis-induced immune suppression. We also found that the sepsis-induced immune suppression depends on generation of TNF-related apoptosis-inducing ligand (TRAIL)-expressing CD8 T cells. These results suggested TRAIL plays an important role in the induction of sepsis-induced immunosuppression, and we used this information to establish a clinically-relevant "two-hit" model of sepsis, which better reflects the delayed mortality seen during sepsis due to the second infection, to investigate sepsis-induced immune suppression of naove and memory Ag-specific CD8 T cell responses to an experimental secondary bacterial infection. Our proposed experiments will investigate the hypothesis that septic (CLP-treated) mice cannot clear a secondary infection because of the systemic suppression of the T cell compartment that is, in part, mediated by a TRAIL-dependent mechanism. Thus, the following distinct but complementary Specific Aims will be evaluated: 1 - Analyze primary CD8 T cell responses to secondary infection after sepsis and determine the role of TRAIL in sepsis- induced immunosuppression, 2 - Determine the extent to which sepsis influences the function of pre-existing memory CD8 T cells and investigate the role of TRAIL in that process, and 3 - Determine the long lasting consequences of sepsis-induced deletion of naove or memory CD8 T cells in vivo. Our experimental design will allow us to define the cellular and molecular mechanism(s) behind the induction and maintenance of sepsis-induced TRAIL-dependent suppression of T cell immunity. We also expect that the data we obtain from these studies will instrumental in the development of new TRAIL-based therapeutic approaches for counteracting the sepsis-induced immune suppression that leads to the high number of deaths seen during this uncontrolled inflammatory response.
描述(由申请人提供): 脓毒症是大多数重症监护病房的主要原因,脓毒症患者的死亡通常不是由最初的脓毒症事件引起,而是由随后的院内感染引起。严重脓毒症幸存的患者通常表现出严重受损的免疫功能。在脓毒症期间,不仅淋巴和骨髓细胞显着凋亡,耗尽免疫系统的关键成分,而且剩余免疫细胞的功能也会下降。对动物和人类的研究表明,脓毒症期间发生的免疫缺陷可能对发病机制和随后的死亡率至关重要。利用盲肠结扎穿刺(CLP)模型诱导腹内腹膜炎,我们最近在脓毒症期间产生的凋亡细胞与脓毒症诱导的免疫抑制的建立之间建立了机制联系。我们还发现脓毒症诱导的免疫抑制取决于表达 TNF 相关凋亡诱导配体 (TRAIL) 的 CD8 T 细胞的产生。这些结果表明TRAIL在脓毒症诱导的免疫抑制的诱导中发挥着重要作用,我们利用这些信息建立了临床相关的脓毒症“二次打击”模型,该模型更好地反映了脓毒症期间由于第二次感染而导致的延迟死亡率,以研究脓毒症诱导的幼稚和记忆Ag特异性CD8 T细胞对实验性继发细菌感染反应的免疫抑制。 我们提出的实验将调查以下假设:脓毒症(CLP 处理的)小鼠无法清除继发感染,因为 T 细胞区室受到系统性抑制,部分是由 TRAIL 依赖性机制介导的。因此,将评估以下不同但互补的具体目标: 1 - 分析脓毒症后继发感染的原代 CD8 T 细胞反应,并确定 TRAIL 在脓毒症诱导的免疫抑制中的作用, 2 - 确定脓毒症影响预先存在的记忆 CD8 T 细胞功能的程度,并研究 TRAIL 在该过程中的作用,以及 3 - 确定脓毒症诱导的幼稚或记忆缺失的长期持续后果 体内 CD8 T 细胞。我们的实验设计将使我们能够定义诱导和维持脓毒症诱导的 TRAIL 依赖性 T 细胞免疫抑制背后的细胞和分子机制。我们还期望从这些研究中获得的数据将有助于开发新的基于 TRAIL 的治疗方法,以抵消脓毒症引起的免疫抑制,这种抑制导致在这种不受控制的炎症反应期间出现大量死亡。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas S Griffith其他文献

Apoptosis-inducing Ligand Cell-mediated Delivery of Tumor Necrosis Factor-related Induction of Glioblastoma Apoptosis Using Neural Stem Updated Version Cited Articles Citing Articles E-mail Alerts Induction of Glioblastoma Apoptosis Using Neural Stem Cell-mediated Delivery of Tumor Necrosis Factor-r
细胞凋亡诱导配体 细胞介导的肿瘤坏死因子相关传递 使用神经干诱导胶质母细胞瘤细胞凋亡 更新版本 被引文章 引用文章 电子邮件提醒 使用神经干细胞介导的肿瘤坏死因子-r 诱导胶质母细胞瘤凋亡
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Moneeb Ehtesham;P. Kabos;M. Gutierrez;N. Chung;Thomas S Griffith;Keith L. Black;John S. Yu
  • 通讯作者:
    John S. Yu
EARLY MICRORECANALIZATION OF VAS DEFERENS AFTER IMPLANTATION OF BIODEGRADABLE GRAFTS IN RATS THAT PREVIOUSLY UNDERWENT BILATERAL VASECTOMY
  • DOI:
    10.1016/s0022-5347(08)61866-2
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Christopher M Simons;Barry R De Young;Thomas S Griffith;Timothy L Ratliff;Surya K Mallapragada;Moshe Wald
  • 通讯作者:
    Moshe Wald
ACTIVATION OF TUMOR-SPECIFIC CD8+ T CELLS AFTER INTRATUMORAL Ad5-TRAIL/CpG ODN COMBINATION THERAPY
  • DOI:
    10.1016/s0022-5347(08)60117-2
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Rebecca L VanOosten;Thomas S Griffith
  • 通讯作者:
    Thomas S Griffith
PHASE I TRIAL OF Ad5-TRAIL-MEDIATED GENE TRANSFER IN MEN WITH LOCALLY-CONFINED PROSTATE CANCER PRIOR TO PLANNED RADICAL PROSTATECTOMY
  • DOI:
    10.1016/s0022-5347(08)61160-x
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Thomas S Griffith;Badrinath R Konety;Fadi N Joudi;Tammy Madsen;Barbara Ziegler;Michael B Cohen;Timothy L Ratliff;Richard D Williams
  • 通讯作者:
    Richard D Williams

Thomas S Griffith的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas S Griffith', 18)}}的其他基金

BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10582394
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
综合使用基因组学、代谢组学和细胞因子分析来验证使用“脏”小鼠研究脓毒症病理生理学
  • 批准号:
    10257687
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
CD4 T cell dysfunction and reprogramming during sepsis
脓毒症期间 CD4 T 细胞功能障碍和重编程
  • 批准号:
    10633073
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
利用微生物暴露研究对尿路致病性大肠杆菌的免疫反应
  • 批准号:
    10413143
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
综合使用基因组学、代谢组学和细胞因子分析来验证使用“脏”小鼠研究脓毒症病理生理学
  • 批准号:
    10512750
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
利用微生物暴露研究对尿路致病性大肠杆菌的免疫反应
  • 批准号:
    10237569
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
CD4 T cell dysfunction and reprogramming during sepsis
脓毒症期间 CD4 T 细胞功能障碍和重编程
  • 批准号:
    10400169
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Alterations in CD4 T cells during sepsis
脓毒症期间 CD4 T 细胞的变化
  • 批准号:
    9101373
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis
脓毒症后 CD4 T 细胞依赖性 B 细胞反应的受损和恢复
  • 批准号:
    10084212
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Suppression of T cell immunity during sepsis
败血症期间 T 细胞免疫的抑制
  • 批准号:
    8237299
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了